Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Nerve Growth Factor (NGF) has been investigated as a potential treatment for peripheral neuropathy due to its critical role in the growth, maintenance, and survival of certain types of neurons, including peripheral sensory neurons. Scientific interest in NGF for peripheral neuropathy stems from preclinical studies showing that exogenous NGF can protect and restore damaged neurons in animal models of neuropathy, such as those induced by diabetes or chemotherapeutic agents. Several early-phase clinical trials in the 1990s and early 2000s evaluated recombinant human NGF (rhNGF) administered subcutaneously for patients with diabetic neuropathy and HIV-associated neuropathy. These studies demonstrated some improvement in sensory function and pain, but the results were inconsistent and often accompanied by significant side effects, such as injection site pain and hyperalgesia. Subsequent larger trials failed to show clear, reproducible clinical benefit, and concerns about adverse events limited further development. As of now, NGF is not approved for peripheral neuropathy treatment, and its clinical use remains experimental. Research interest persists, with ongoing efforts to develop NGF mimetics or alternative delivery methods to mitigate side effects. In summary, while there is a scientific rationale and early clinical research supporting the use of NGF for peripheral neuropathy, robust and consistent clinical evidence is lacking, resulting in a low overall evidence rating.

More about Nerve growth factor
More about Peripheral Neuropathy

Other ingredients used for Peripheral Neuropathy

Other health conditions supported by Nerve growth factor

Products containing Nerve growth factor